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Abstract
Background: The antiproliferative effect of the Hsp90 inhibitor 17-AAG (17-allylamino-17-demethoxygeldanamycin) 
on human retinal pigment epithelial cells is investigated.
Methods: MTT and flow cytometry were used to study the antiproliferative effects of the 17-AAG treatment of ARPE-19 
cells. 2D gel electrophoresis (2-DE) and mass spectrometry were applied to detect the altered expression of proteins, 
which was verified by real-time PCR. Gene Ontology analysis and Ingenuity Pathway Analysis (IPA) were utilized to 
analyze the signaling pathways, cellular location, function, and network connections of the identified proteins. And 
SOD assay was employed to confirm the analysis.
Results: 17-AAG suppressed the proliferation of ARPE-19 cells by inducing cell cycle arrest and apoptosis. Proteomic 
analysis revealed that the expression of 94 proteins was altered by a factor of more than 1.5 following exposure to 17-
AAG. Of these 94, 87 proteins were identified. Real-time PCR results indicated that Hsp90 and Hsp70, which were not 
identified by proteomic analysis, were both upregulated upon 17-AAG treatment. IPA revealed that most of the 
proteins have functions that are related to oxidative stress, as verified by SOD assay, while canonical pathway analysis 
revealed glycolysis/gluconeogenesis.
Conclusions: 17-AAG suppressed the proliferation of ARPE-19 cells by inducing cell cycle arrest and apoptosis, and 
possibly by oxidative stress.
Background
The pathogenesis of some eye diseases involves the pro-
liferation of retinal pigment epithelial (RPE) cells. For
example, proliferative vitreoretinopathy (PVR) is respon-
sible for most failures of the repair of retinal detachment
following retinal reattachment surgery or severe ocular
trauma, potentially resulting in significant loss of vision
[1]. Although vitrectomy is helpful in reducing traction
on the retina, removing vitreous opacities, and providing
access to the vitreous cavity and retina in many surgical
procedures, the rate of recurrence that ultimately leads to
vision loss is high. Additional methods are required to
prevent the formation of epiretinal membranes and con-
traction following vitreous surgery. Early PVR is charac-
terized by dedifferentiation, migration, and proliferation
of different cells, including fibroblasts, glial and RPE cells
at the vitreoretinal interface, leading to the formation of
contractile fibrocellular membranes on the surface of the
retina. The proliferation and migration of RPE cells is an
important step in PVR. RPE cells detach from the mono-
layer, migrate into the vitreous cavity and settle on the
retina, forming a periretinal membrane. Since RPE cells
are the main cells that are involved in the pathogenesis of
PVR, research into therapies for PVR tend to focus on
RPE cells. The inhibition of either RPE migration or RPE
proliferation is a reasonable target for the development of
drugs for treating PVR, so many chemotherapeutic
agents have been used to inhibit the proliferation or
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migration of RPE cells to ameliorate PVR [[1,2] and [3]].
Most investigations, however, have not been successful.
Numerous antiproliferative and anti-inflammatory
agents, such as retinoic acid, corticosteroid, and 5-fluo-
rouracil (5-FU) have been tested to evaluate their poten-
tial to prevent the proliferation and migration of RPE
cells, and thereby reduce traction retinal detachment in
experimental models of PVR. Most of these drugs (many
of which are antitumor drugs) have limited clinical appli-
cation because of their toxicity [1,2]. Recently, a new anti-
tumor drug, 17-AAG (17-allylamino-17-demethoxy-
geldanamycin), was developed. Results from adult phase I
studies reveal that 17-AAG can be administered without
excessive toxicity, down-regulating several biomarkers,
such as Raf-1, CDK4, Akt and others [4,5]. Hence, we
hypothesize that this new drug may inhibit the prolifera-
tion of RPE cells, and may be effective in the treatment of
PVR.
17-AAG, a derivative of the ansamycin geldanamycin, is
less hepatotoxic than geldanamycin. Both 17-AAG and
geldanamycin induce cell cycle arrest and apoptosis in
various tumors. 17-AAG, which interferes with the func-
tion of Hsp90 (heat shock protein 90), is currently under-
going phase II/III clinical trials as the first Hsp90
inhibitor to treat tumors. Hsp90 is a chaperone protein
that participates in the regulation of the intracellular dis-
position of diverse cellular proteins, including the com-
ponents of signaling pathways that are exploited by
cancer cells for survival and proliferation [6]. The inhibi-
tion of Hsp90 disrupts the folding of these proteins,
increasing their susceptibility to ubiquitinization and
proteasomal degradation. The exposure of cells to 17-
AAG or geldanamycin down-regulates the expression of
diverse signal transduction and cell cycle regulatory pro-
teins, including Raf-1, cyclin D, and Akt, among others
[7,8]. The Hsp90 inhibitor geldanamycin inhibits RPE cell
proliferation [9]. However, the full range of effects of
Hsp90 inhibition in RPE cells are unknown.
Proteomic analysis is a valuable method for elucidating
the molecular nature of Hsp90 inhibition. Many research-
ers have used it to study cellular protein changes follow-
ing exposure of cancer cell lines to 17-AAG or
geldanamycin or other Hsp90 inhibitors [[6,10] and [11]].
This work tested the antiproliferative effects of 17-AAG
on the human RPE cell line ARPE-19, as well as the
change in protein expression. Real-time PCR was used to
verify the change in expression of selected genes that
were identified by proteomic analysis, as well as changes
in the expression of Hsp90 and Hsp70, which were not
thus identified. Gene Ontology analysis and Ingenuity
Pathways Analysis (IPA) was applied to analyze the
molecular functions, signal pathways, cellular location
and network connections of the proteins, as well as their
possible involvement in disease processes.
Methods
Human RPE cell culture and reagents
The human RPE cell line ARPE-19 (American Type Cul-
ture Collection, Manassas, VA) was cultured in DMEM/
F12 (Hyclone, Logan, UT) supplemented with 10% fetal
calf serum (FCS; Gibco, Grand Island, NY), 100 μg/ml
penicillin and 100 μg/ml streptomycin (both from Gibco)
and maintained at 37°C and 5% CO2 in a humid atmo-
sphere. In all experiments, dimethyl sulfoxide (DMSO;
Sigma-Aldrich, St. Louis, MO) was added as a negative
control. 17-AAG (Sigma-Aldrich) was dissolved in
DMSO, which was then stored at -20°C.
Cell viability analysis
ARPE-19 cells were seeded in 96-well plates, in 100 μl of
growth medium. Following an overnight attachment
period, the cells were exposed to various concentrations
of 17-AAG (0, 0.05, 0.1, 0.5, 1, 5 and 10 μM). All studies
were performed at least three times independently. At the
end of the treatment period (24, 48 or 72 h), 20 μl of a 5
mg/ml stock solution of 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich)
was added to each well. Four hours later, 150 μl DMSO
was added to dissolve the dark blue formazan crystals
that were formed by the living cells. The absorbance of
each well at 490 nm (A490) was determined using a Bio-
Rad model 450 microplate reader (Bio-Rad Laboratories,
Richmond, CA). The background A490 of the wells that
did not contain cells was subtracted before the percent-
age of viable cells was calculated [(A490 of 17-AAG treated
sample/A490 untreated cells) × 100%].
Annexin-V and Propidium Iodide (PI) staining
To identify cells in the early and late stages of apoptosis,
the Annexin V-FITC Apoptosis Detection Kit was applied
(BD PharMingen, San Diego, CA). Briefly, ARPE-19 cells
were cultured with 3 μM 17-AAG for 24, 48 or 72 h,
trypsinized and washed twice with cold PBS (phosphate-
buffered saline), and then resuspended in 1 × binding
buffer (BD PharMingen) at a concentration of 1 × 106
cells/ml. One hundred μl of the cell suspension was trans-
ferred to a 5 ml polypropylene tube, and 5 μl each of PI
(50 μg/ml stock) and annexin V-FITC were added simul-
taneously. The cells were gently mixed and incubated at
room temperature in the dark for 15 min. Three hundred
μl of 1 × binding buffer was added to each tube, and the
cells were analyzed immediately by flow cytometry (FAC-
Scan, Becton Dickinson, Franklin Lakes, NJ). The mor-
phology of ARPE-19 cells that were treated with DMSO
or various concentrations of 17-AAG (0.5 μM, 3 μM, 10
μM) for 24 h was recorded by visualizing the cells under
an Olympus U-LH100HG light microscope (Olympus,
Tokyo, Japan).Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
Page 3 of 15
Cell cycle analysis by flow cytometry
ARPE-19 cells were cultured with 3 μM 17-AAG for 24,
48 or 72 h, and then collected, washed twice with ice-cold
1× PBS, and fixed with 70% ethanol overnight at -20°C.
Cell pellets were washed twice with ice-cold PBS, resus-
pended in PBS, and stained with PI that contained 100
μg/ml RNAse (Sigma-Aldrich). Stained cells were main-
tained on ice and protected from light. They were then
analyzed on the FACScan flow cytometer, as described
above. Data were analyzed using CellQuest Software
(Becton Dickinson, Mountain View, CA).
Isolation of cellular proteins
To prepare protein lysates from ARPE-19 cells prepara-
tions, the cells were incubated with 3 μM 17-AAG or
DMSO for 16 h. Each treatment was performed in tripli-
cate. After the cells were trypsinized and washed twice
with PBS, 200 μl lysis buffer [7 M urea, 2 M thiourea, 4%
(w/v) CHAPS, 1% (w/v) dithiothreitol (DTT), 1% Pro-
tease Inhibitor Cocktail (v/v), and 2% (v/v) IPG buffer
(pH 3-10)] were added at 11,000 IU/min on ice (in ten
bursts of 10 s each, separated by short pauses). Suspen-
sions then were stored at 4°C for 1 h, before undergoing
centrifugation at 40,000 × g for 60 min at 4°C. The super-
natants were aliquoted and stored at -70°C. The protein
concentration of each sample was measured by the Brad-
ford method [12].
Two-Dimensional Electrophoresis (2-DE)
Isoelectric focusing (IEF) was conducted using an Ettan
IPGphor II (Amersham Bioscience, Uppsala, Sweden)
with 24 cm immobilized pH gradient strips (pH 3-10;
Amersham Bioscience). Samples that contained 300 μg of
protein were mixed with rehydration solution [8 M urea,
2% CHAPS, 20 mM DTT, 0.5% (v/v) IPG buffer (pH 3-
10), and 0.001% bromophenol blue]. The linear ramping
mode of the IEF voltage was used as follows; 30 V for 6 h,
60 V for 6 h, 500 V for 1 h, 1000 V for 1 h, and 3000 V for
1 h, followed by 8000 V for approximately 7.5 h, to
achieve 64 kVh at 20°C. Strips were then equilibrated at
room temperature for 15 min in 10 ml equilibration solu-
tion [6 M urea, 50 mM Tris-HCl (pH8.8), 30% (v/v) glyc-
erol, 2% sodium dodecyl sulfate (SDS), 1% (w/v) DTT]
and incubated for another 15 min in an equilibration
solution that was the same as previously used, except
with DTT replaced by 2.5% (w/v) iodoacetamide]. Sec-
ond-dimension electrophoresis was carried out on 12.5%
SDS gels in the Ettan DALTsix at 5 W per gel for the first
30 min, followed by 12 W per gel for 6-7 h until the bro-
mophenol blue line reached the bottom of the gels. Gels
(three of each) were then silver-stained to visualize the
in-gel proteins, following published methods described
elsewhere [12].
Silver-stained gels were scanned using an Atrix scan
1010 plus (Microtek, Taiwan, China), and the resulting
images were analyzed using the ImageMaster 2D Plati-
num software (Amersham Bioscience) for spot detection,
quantification, and comparative and statistical analyses.
The mean and SD normalized volume of each protein
spot were calculated, and statistical comparisons between
the intensity of the control and the 17-AAG treated spots
were conducted using Student't-test (with p < 0.05 con-
sidered significant) [13].
In-Gel digestion and MALDI-TOF analysis
Detected spots and four control spots (with volumes of
around 1 mm3) were excised from the silver-stained gels
and the nonstained areas of the gels, respectively. For in-
gel protein digestion, the gel-bound proteins were
w a s h e d  a t  r o o m  t e m p e r a t u r e  w i t h  5 0  m M  a c e t o n i t r i l e
(ACN)/NH4HCO3 1:1(v/v), once for 10 min and once for
30 min, dehydrated in 20 μl ACN for 20 min, and then
dried in a vacuum centrifuge (Eppendorf AG, Hamburg,
Germany) for 30 min at 30°C. Proteins were reduced by
incubation in 50 μl 10 mM DTT/25 mM NH4HCO3 at
56°C for 1 h and then alkylated in 50 μl 55 mM iodoacet-
amide/25 mM NH4HCO3 for 45 min at room tempera-
ture in the dark. The liquid was discarded, and gel pieces
were washed twice in 25 mM NH4HCO3, dehydrated in
ACN, and dried in a vacuum centrifuge for 30 min at
30°C. Gel pieces were then rehydrated in 4 μl 25 mM
NH4HCO3 that contained 40 ng trypsin and incubated at
4°C for 1 h. Excess liquid was discarded and gel plugs
were incubated overnight at 37°C, with tubes inverted to
keep the gel pieces wet to ensure sufficient enzymatic
cleavage. Then, 8 μl of 5% (v/v) trifluoroacetic acid (TFA)
was added and samples were incubated at 37°C for 1 h;
supernatants were collected and the proteins were
extracted twice by incubating the gel pieces in 8 μl of 2.5%
TFA/50% ACN at 37°C for 1 h. Supernatants were mixed
and completely dried in a vacuum centrifuge. The result-
ing peptides were maintained at 4°C until they were ana-
lyzed on a mass spectrometer.
For MALDI-TOF (matrix-assisted laser desorption ion-
ization-time of flight) analysis, the dried peptides were
dissolved in 2 μl 0.5% TFA. The matrix material was dis-
solved in TA solution to saturation (ACN: 0.1% TFA: ace-
tone = 3:6:1). The matrix and the analyte solution were
mixed in a ratio of 1:1, and 1 μl of the mixture was depos-
ited onto the stainless steel sample target. The solvent
was allowed to evaporate at room temperature. MALDI-
TOF analysis of trypsin digests was performed using a
Bruker Biflex IV MALDI-TOF-MS (Bruker Daltonics,
Germany) that was equipped with an N2 laser (337 nm, 3
ns pulse length) in positive ion mode at an accelerating
voltage of 19 kV. Peptide data were collected in the reflec-Yao et al. Journal of Biomedical Science 2010, 17:30
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tron mode. Each spectrum was formed from around 200
laser shots. External calibration for peptide analysis was
performed using peptide calibration standards [12].
Database research
Data were screened against the SWISS-PROT database
using the MASCOT search program http://www.matrix-
science.com. Searches were performed using peptide
mass accuracy tolerances of 0.3 Da or 200 ppm for exter-
nal calibration. Peptides in the blank controls were
excluded. One missed cleavage per peptide was allowed.
The variable modification was considered to be carbami-
domethyl (C). The requirements for positiviely identify-
ing proteins were as follows: (1) at least three matching
peptide masses; and (2) molecular weight and isoelectric
points (pI) of identified proteins should be consistent
with the values estimated from the image analysis.
RNA extraction and cDNA synthesis
For real-time PCR measurements, the ARPE-19 cells
were treated with either 3 μM 17-AAG for 16, 24 or 48 h,
or 2, 5, or 10 μM 17-AAG for 24 h. Total RNA was
extracted from each sample using TRIzol (Invitrogen,
Carlsbad, CA) following the manufacturer's instructions.
The RNA concentration was determined by measuring
the absorbance at 260 nm using a spectrophotometer.
The extracted total RNA was treated with RNase-free
DNase I to eliminate potential contamination by genomic
DNA. Around 1 μg of total RNA from each sample was
used in the synthesis of the first strand of cDNA. The
synthesis of the first-strand cDNA was primed using
oligo (dT) from the SuperScript III First-Strand synthesis
kit (Invitrogen). The synthesized cDNA was used as a
template to estimate the quantity of gene transcription by
real-time PCR.
Real-time PCR
Real-time PCR was used to confirm the 2-DE results con-
cerning changes to the transcription of proteins. Real-
time PCR was carried out using an ABI PRISM1 7300
Sequence Detection System (Applied Biosystems, Foster
City, CA) and a TaqMan PCR Master Mix (Applied Bio-
systems) with a final volume of 20 μl. β-actin was the
internal control. The PCR amplification protocol was as
follows; 50°C for 2 min and 95°C for 10 min, followed by
40 cycles of 95°C for 15 s and 60°C for 30 s. Table 1 pres-
ents the primers and probes of the internal control and
target genes. Each sample, including the internal control,
was tested in triplicate. Each sample that was treated with
17-AAG was compared with one treated with the same
volume of DMSO using the 2-ΔΔCT method [14].
Analysis of molecular functions and pathway 
usingbioinformatics
Regulated proteins identified by 2-DE were analyzed fur-
ther by Gene Ontology (GO) analysis and Ingenuity Path-
way Analysis (IPA; Ingenuity Systems, Mountain View,
CA;http://www.ingenuity.com). GO is a structured, con-
trolled vocabulary that describes geneproducts in terms
of their associated biological processes, cellular compo-
nents and molecular functions in a manner that does not
depend on species [15]. IPA was used as described by the
manufacturer to model specific physiological processes
that were influenced by exposure to 17-AAG. Each gene
name was mapped to its corresponding gene object
(node) in the Ingenuity Pathways Knowledge Base
(IPKB). The magnitude and direction of changes to the
gene objects were determined by forming a ratio between
them, which reveals statistically significant changes
caused by exposure to 17-AAG as well as their control
levels before exposure. To obtain as complete a picture as
possible, the ratios for the increased and decreased gene
objects were combined into a single dataset. The IPA pro-
gram treated these ratios as change factors, and gene
objects whose changed by a factor of at least two were
overlaid onto a global molecular network that was devel-
oped from information that was contained in the IPKB.
Networks were then algorithmically generated based on
their connectivity.
SOD assay
The ARPE-19 cells were treated with 3 μM 17-AAG for
16, 24 or 48 h, and then SOD activity was determined
using an SOD Assay Kit-WST (Dojindo Molecular Tech-
nologies, Inc. Japan) following the manufacturer's direc-
t i o n s .  C e l l s  w i t h  a d d e d  D M S O  w e r e  u s e d  a s  c o n t r o l s.
This kit supports highly sensitive SOD assay using a
highly water-soluble tetrazolium salt, WST-1 [2-(4-iodo-
phenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfo-phenyl)-2H-
tetrazolium, monosodium salt], which forms a water-sol-
uble formazan dye upon reduction by a superoxide anion.
A colorimetric assay is employed to measure the amount
of formazan produced by the reaction between WST-1
and the superoxide anion (O2
-); the rate of reduction with
O2
- is linearly related to the xanthine oxidase activity
which is inhibited by SOD. The absorbance was obtained
using a microplate reader at 450 nm. SOD activity (inhi-
bition rate %) = [(A blank1 - Ablank3) - (Asample - Ablank2)]/
(Ablank1 - Ablank3) × 100. SOD activity per well was deter-
mined from the standard curve, and the amount of SOD
per cell was calculated. Data were normalized to the con-
trol.
Statistical analysis
All experiments were performed in triplicate and all data
were presented as mean ± S.D. When applicable, differ-
ences between two groups were determined using the
unpaired Student's t-test. For multigroup comparisons,
ANOVA and then a Student-Newman-Keuls test were
performed. P < 0.05 was regarded as statistically signifi-
cant.Yao et al. Journal of Biomedical Science 2010, 17:30
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Results
17-AAG inhibited proliferatin of RPE cells
To study the biological effect of the inhibition of Hsp90 in
ARPE-19 cells, the cells were incubated with increasing
doses of 17-AAG (0 - 10 μM), and cell viability in each
case was evaluated using the MTT proliferation assay. 17-
AAG reduced cell viability in a dose-dependent manner
(p < 0.05). No time-dependent decrease in viability
occurred, regardless of the concentration of 17-AAG (p >
0.05). Viability at 72 h recovered slightly (Fig. 1). To pre-
vent excessive apoptosis, a concentration of 3 μM was
selected for the following experiments.
17-AAG induces apoptosis in ARPE-19 cells
ARPE-19 cells were incubated with 3 μM 17-AAG or the
same volume of DMSO for up to 72 h. The cells were then
incubated with Annexin V-FITC in a buffer that con-
tained PI and analyzed by flow cytometry. Most of the
untreated cells were Annexin V-FITC and PI negative
(Fig. 2, lower left quadrant), indicating that the cells were
viable and did not undergo apoptosis. Following treat-
ment with 17-AAG, a number of cells were Annexin V-
FITC-positive but PI-negative (lower right quadrant),
suggesting that they were in the early stages of apoptosis.
Furthermore, a significant population of cells had pro-
gressed to a later stage of apoptosis and were stained by
both PI and Annexin V. 17-AAG caused morphological
changes when added to ARPE-19 cells, since numerous
cells were detached and floated to the top of the culture
medium, where they were shrunken and dispersed. The
changes in cell morphology became increased as the con-
centration increased (data not shown). The induction of
apoptosis was preceded by cell cycle arrest. The treat-
ment of ARPE-19 cells with 17-AAG induced G1 cell
cycle arrest as determined by comparison with control
cells (Fig. 3).
2-DE and image analysis
The images of silver-stained gels were analyzed using
ImageMaster 2D Platinum software. Figures 4A and 4B
show images of control and those treated with 17-AAG.
Based on a 1.5-fold change cutoff, the analysis identified
94 proteins (Fig. 4), while MALDI-TOF analysis identi-
fied 87 proteins whose expression was altered. Additional
file 1 and 2 present the name, IPI Accession number,
Table 1: Primers and probes for real-time PCR.
Gene ID Gene name Sequence* Amplicon size(bp)
NM_000925 PDHB F: 5'-GAAACCATAGAAGCCAGTGTCA-3'
R: 5'-TCTTTGCATAAGGCATAGGGA-3'
P: 5'-TGTGGAAGGAGGCTGGCCACA-3'
181
NM_005809 PRDX2 F: 5'-AGGTGAAGCTGTCGGACTACA-3'
R: 5'-TGCTGAACGCGATGATCTC-3'
P:5'-CGTGGTCCTCTTTTTCTACCCTCTGGA-3'
99
NM_006406 PRDX4 F: 5'-CACTTCTACGCGGGTGGA-3'
R: 5'-CGCTGGCTTGGAAATCTT-3'
P: 5'-CGCCGACCACTCCCTGCACC-3'
102
NM_005345 HSPA1A F: 5'-CTGCGACAGTCCACTACCTTTT-3'
R: 5'-TCCCTGCTCTCTGTCGGC-3'
P: 5'-CCAAGGCTTCCCAGAGCGAAC-3'
187
NM_002156 HSPD1 F: 5'-GGAGTGGCTGTGCTGAAGGT-3'
R: 5'-GCATCGAAGGAGGGCACA-3'
P: 5'-CTGCTGTTGAAGAAGGCATTGTTTTG-3'
144
NM_001017963 HSP90AA1 F: 5'-TTCAGACAGAGCCAAGGTGC-3'
R: 5'-CAATGACATCAACTGGGCAAT-3'
P: 5'-CCCAGACCCAAGACCAACCGATGG-3'
168
NM_007355 HSP90AB1 F: 5'-GGCAGTCAAGCACTTTTCTGTAG-3'
R: 5'-GTCAACCACACCACGGATAAA-3'
P: 5'-ATTGCTATTTATTCCTCGTCGGGCT-3'
199
NM_002046 GAPDH F: 5-TGCACCACCAACTGCTTAGC-3'
R: 5'-TCTTCTGGGTGGCAGTGATG-3'
P: 5'-ATGGACTGTGGTCATGAGTCCTTCCA-3'
106
NM_001100 β-actin F: 5'-GGCACCCAGCACAATGAA-3'
R: 5'-GGAAGGTGGACAGCGAGG-3'
P: 5'-CAAGATCATTGCTCCTCCTGAGCGC-3'
98
*F: forward; R: reverse; P: probeYao et al. Journal of Biomedical Science 2010, 17:30
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function, molecular weight and isoelectric point of each
protein.
Confirming altered expression with real-time PCR
Real-time PCR, which rapidly and precisely quantifies
gene expression levels, was utilized to verify the deter-
mined changes in protein expression. Five specific pro-
teins that were differentially regulated by 17-AAG were
selected, and their gene expression in response to the
treatment of ARPE-19 cells by 17-AAG was quantified.
Figure 5 displays the five selected regions of 2D gels,
revealing individual protein expression changes upon
exposure to 3 μM 17-AAG for 16 h. Proteomic analysis
did not identify HSPA1A (Hsp70), HSP90AA1 (Hsp90α)
or HAP90AB1 (Hsp90β), but they are commonly
reported to change upon treatment with 17-AAG, and
were also detected by real-time PCR. The real-time PCR
verified the changes of the five selected proteins. Another
three unidentified proteins were all upregulated by 17-
AAG treatment, but their upregulation declined in a time
and dose-dependent manner. Even Hsp90β was sup-
pressed upon exposure to 10 μM 17-AAG for 24 h or 3
μM 17-AAG for 48 h. Notably, Hsp70 and Hsp90α were
upregulated by a factor of more than 12 after 16 h of
treatment with 3 μM 17-AAG (Figs. 6A and 6B).
Bioinformatics analysis
To identify major molecular functions that were affected
by 17-AAG, the protein dataset was subjected to Gene
Ontology (GO) analysis. Molecular functions that
involved the most identified proteins were executed
(Additional file 1 and 2 and Fig. 7A). Many proteins
mapped to multiple functions. Catalytic activity
accounted for 52% of the identified proteins, which were
grouped into oxidoreductase (21%), hydrolase (13%),
transferase (9%), lyase (6%), and isomerase (3%). Protein
binding (16%) and actin binding (5%) were also major
functions.
Ingenuity Pathways Analysis (IPA) was used to identify
biological networks that were affected by 17-AAG. The
87 unique IPI accession numbers in Additional file 1 and
2 were analyzed for network associations of them using
the Ingenuity Knowledge base, a curated database of pub-
licly available pathways and relationships. Most identified
proteins were located in the cytoplasm (Fig. 7B). The top
function in the list was oxidative stress (Fig. 8). Six high
ranking networks were identified. Figure 9 shows the top-
ranked network. The significance of the association
between the data set and the canonical pathway was mea-
sured in two ways: (1) a ratio of the number of genes from
the data set that map to the pathway to the total number
of genes that map to the canonical pathway is given; (2)
Fischer's exact test was performed to calculate a p value
for the probability that the association between the genes
in the dataset and the canonical pathway is explained by
chance alone. A pathway with a significance of less than
0.05 was regarded as significantly regulated.
SOD assay
To confirm the results of IPA, an SOD assay was utilized.
Following incubation with 3 μM 17-AAG, the SOD activ-
ity in RPE cells was upregulated in 16 h and downregu-
lated after 24 h, by comparison with a control, verifying
the results of proteomics (Fig. 10).
Discussion
Hsp90 is a molecular chaperone which facilitates the
folding and stabilization of numerous protein kinases and
intracellular signaling molecules. Hsp90 is a potential tar-
get for pharmacological inhibition in various cancer cells
[16]. The inhibition of Hsp90 by 17-AAG or other Hsp90
inhibitors has a potent antitumor effect. The antiprolifer-
ative effects of 17-AAG and other Hsp90 inhibitors have
been extensively studied in numerous cell lines. 17-AAG
inhibits three signaling pathways - Raf/MEK/ERK, PI3K/
AKT, and p38/MAPK - by inhibiting the activity of at
least one member of the pathway [17,18]. All of these
pathways may be involved in the proliferation of RPE
cells, and inhibiting one of these pathways leads to the
apoptosis of RPE cells [19,20]. 17-AAG inhibits the activ-
ity of cell cycle proteins, such as CDK4 and CDK6, and
induces cell cycle arrest. 17-AAG also can induce apopto-
sis by activating caspases or in a caspase-independent
manner [21]. 17-AAG also inhibits the function of some
cytokines that are associated with PVR, such as EGF and
PDGF, by inhibiting the interaction of Hsp90 with their
Figure 1 17-AAG suppresses RPE cells proliferation. ARPE-19 cells 
were treated with various concentrations of 17-AAG for 24, 48, or 72 h. 
Their viability was evaluated using the MTT assay, as described in the 
Methods section. Values are presented as means ± SD for triplicate cul-
tures of each cell and are presented as the percentage of control cells 
that received medium only. 17-AAG reduces the viability of ARPE-19 
cells in a dose-dependent manner (p < 0.05). No time-dependent de-
crease in viability occurs, regardless of the concentration of 17-AAG (p 
> 0.05). *, p < 0.05.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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receptors [22]. The authors' earlier investigation indi-
cated that 17-AAG downregulates Akt-1, Raf-1 [8], and
PDGFR [23] in ARPE-19 cells.
This work demonstrates that an Hsp90 inhibitor, 17-
AAG, has a potent antiproliferative effect on ARPE-19
c e lls by inducing ce ll cycle arrest and a popt osis. MTT
proliferation assay revealed the absence of a time-depen-
dent decrease in viability, but flow cytometry indicated a
time-dependent decline in apoptosis in the cells that were
treated with 17-AAG. Because of the difference between
the MTT analysis and flow cytometry, and the difference
between the concentrations of 17-AAG used in the two
methods herein, this discrepancy may be acceptable.
To investigate the mechanism of the antiproliferation
effect of 17-AAG on ARPE-19 cells, changes in protein
expression caused by treatment with 17-AAG were exam-
ined by 2-DE and MALDI-TOF. The 16 h time point was
chosen because most of the proteins in other cell lines
changed within 16 hours of treatment with 17-AAG [24].
Proteomics analysis (2-D electrophoresis and MALDI-
TOF mass spectrometry) combined with bioinformatics
analysis also revealed that catalytic activity accounted for
52% of the identified proteins and 17-AAG may inhibit
the proliferation of ARPE-19 cells and induce aopotosis
in part by inducing oxidative stress.
The proteins that were downregulated in RPE by 17-
AAG included several glycometabolism-associated
enzymes, including PDHB (pyruvate dehydrogenase),
LDHB (L-lactate dehydrogenase B chain), TPI1 (isoform
1 of triosephosphate isomerase) and ALDOA (fructose-
Figure 2 17-AAG induces apoptosis in ARPE-19 cells. Following incubation with 3 μM 17-AAG for 24, 48 or 72 h, apoptosis was assessed using a 
flow cytometer to detect cells that were stained with Annexin V or PI, as described in the Methods section. Exposure to 17-AAG causes a significant 
population of ARPE-19 cells to proceed to a later stage of apoptosis.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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Figure 3 The treatment of ARPE-19 cells with 17-AAG induces G1 cell cycle arrest. After incubation with 3 μM 17-AAG for 24, 48 or 72 h, cell cycle 
progression was evaluated by flow cytometry, as described in the Methods section. 17-AAG induces G1 cell cycle arrest in ARPE-19 cells.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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bisphosphate aldolase A). A canonical pathways analysis
of IPA also highlighted one major pathway, glycolysis/glu-
coneogenesis. Some researchers have reported that the
inhibition of Hsp90 influences metabolic pathways and a
large-scale Hsp90-interactomic survey in yeast has
revealed a huge proportion of metabolic enzymes as pos-
sible Hsp90 substrates. Hsp90 may also act as a physio-
logical ATP sensor by regulating the stability of growth-
signaling cascades in relation to cellular energy charge,
and network simulations reveal that molecular chaper-
ones counterbalance perturbations in protein-folding
dynamics that are associated with the sudden drops in
ATP levels in diseased cells [25]. Therefore, the downreg-
ulation of these proteins suggests that 17-AAG may
reduce cell proliferation, at least in part, by reducing ATP
synthesis.
Some antiproliferative proteins, including GLUD1 (glu-
tamate dehydrogenase 1), were upregulated and some
proteins associated with the development and progres-
sion of tumors were downregulated upon exposure to 17-
AAG. Glutamate activates the Ras/Raf/MEK/ERK cas-
cade, and accelerates RPE cell proliferation [26]. Many
proteins associated with cell structure and cell motility
were also upregulated, including PLOD2 (procollagen-
lysine, 2-oxoglutarate 5-dioxygenase 2), Moesin, Cofilin-
1, FBXL17 (F-box and leucine-rich repeat protein 17) and
CAPZA2 (F-actin capping protein subunit alpha-2).
Some were downregulated, including STMN1 (Stathmin
1), LGALS1 (Galectin-1), PFN1 (Profilin-1) and COTL1
(Coactosin-like protein). Since molecular chaperones are
involved differently but cooperatively in the formation
and function of the eukaryotic cell cytoskeleton, inhibit-
ing Hsp90 may change the expression of these proteins
[27].
Proteins that are associated with ubiquitin-mediated
proteasomal degradation mechanisms were differentially
expressed [increased: PSMD14 (26S proteasome non-
ATPase regulatory subunit 14), PSMC2 (26S protease
regulatory subunit 7), PSMB2 (Proteasome subunit beta
type-2); decreased: PSME1 (proteasome activator subunit
1 isoform 2), PSMB4 (Proteasome subunit beta type-4),
PSMA1 (Isoform Short of Proteasome subunit alpha
type-1)]. PSME1 not only activates the peptidase activity
of 20 S proteasome, but also has a critical role as a cofac-
tor which functions in concert with Hsc70 and Hsp40
during Hsp90-dependent protein refolding [28]. Interest-
ingly, glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) was also downregulated, which was verified by
the real-time PCR results obtained herein. And Hsp90 is
Figure 4 2-DE reveals protein expression in untreated ARPE-19 cells or ARPE-19 cells exposed to 17-AAG. Isoelectric focusing followed by sec-
ond-dimension electrophoresis was carried out using protein lysates from ARPE-19 cells incubated with 3 μM 17-AAG or DMSO for 16 h. Gels (three 
of each) were then silver-stained and scanned, and the resulting images were analyzed using the ImageMaster 2D Platinum software for spot detec-
tion, quantification, and comparative and statistical analyses as described in the Methods section. 2-DE reveals protein expression in untreated ARPE-
19 cells (A) or ARPE-19 cells exposed to 17-AAG (B). The green labels identify proteins whose expression is altered by a factor of greater than 1.5 in the 
treated cells.
Figure 5 Selected regions of 2D gels, showing changes in protein 
expression following treatment with 17-AAG. Expression of protein 
in the 2D gels by HSPD1, PRDX2, PRDX4, PDHB and GAPDH following 
exposure to 3 μM 17-AAG for 16 h.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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Figure 6 Dose- and time-dependent changes in expression of selected genes upon exposure to 17-AAG. After the ARPE-19 cells were treated 
with either 3 μM 17-AAG for 16, 24 or 48 h, or 2, 5, or 10 μM 17-AAG for 24 h, total RNA from each sample was extracted and reverse transcribed into 
cDNA. Changes in the expression of proteins were verified by real-time quantitative PCR. The dose (A) and time (B) -dependent changes were both 
evaluated as mean ± SD. The changes in selected genes are consistent with the results of proteomics. Another three unidentified proteins, Hsp70, 
Hsp90α and Hsp90β, were all upregulated by 17-AAG treatment, but their upregulation declined in a time and dose-dependent manner.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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Figure 7 Functional classification and subcellular localization of identified proteins based on bioinformatics. Regulated proteins identified 
by 2-DE were analyzed further by Gene Ontology (GO) analysis and Ingenuity Pathway Analysis (IPA). GO analysis for functional classification of pro-
teins identified by proteomics. Catalysis and protein binding are major functions of the identified proteins (A). IPA of subcellular localization of iden-
tified proteins, most of which are located in cytoplasm (B).
Figure 8 Differentially expressed genes associated with a canonical pathway in the Ingenuity Pathway Analysis. IPA was applied to model 
specific physiological processes that were affected by exposure to 17-AAG. Each gene name was mapped to its corresponding gene object (node) in 
the Ingenuity Pathways Knowledge Base (IPKB). Top function in the list is oxidative stress.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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Figure 9 Network that contains the largest number of differentially expressed proteins. IPA was employed to identify biological networks that 
were affected by 17-AAG. The 87 unique IPI accession numbers were analyzed for network associations by the Ingenuity Knowledge base and six high 
ranking networks were identified. The top-ranked network comprises 35 proteins, including 29 that were identified by proteomics and six that were 
recognized as related to the network because of their reported interactions with the proteins that were identified by difference gel electrophoresis 
(DIGE). Shaded nodes are derived from dataset of proteins identified by 2D, and white nodes are inserted by the IPA program. Green represents a 
decrease, while red denotes an increase. Nodes are displayed using various shapes that represent the functional class of the gene product: concentric 
circles represent a group or complex; down-pointing triangles represent kinases; diamonds represents other enzymes; horizontal ovals represent tran-
scription regulators; vertical ovals represent transmembrane receptors; vertical rectangles represent G-protein coupled receptors; horizontal rectan-
gles represent ligand-dependent nuclear receptors, and circles represent other entities. Solid lines indicate direct interactions between nodes 
whereas dashed lines represent indirect interactions. Lines beginning and ending at a single node show self-regulation, while a line without an arrow-
head represents binding. Arrowheads represent directionality of the relationship.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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reported to interact with GAPDH in HEK293 cells [29].
This protein is commonly used as an internal control in
Western blots or real-time PCR. Although GAPDH
changed slightly as the concentration of 17-AAG
increased, GAPDH should not be used as the internal
control in 17-AAG treatment research, especially in RPE
cells.
Although several attempts were made herein to identify
all of the proteins, there seven proteins whose changed by
a factor of more than 1.5-fold were not identified. Neither
Hsp90 nor Hsp70 was identified in this experiment,
despite having been identified elsewhere [6,10]. Real-time
PCR herein revealed that they were both upregulated
after 16 h of treatment with 17-AAG. However, the
expression level of Hsp90 is not correlated with inhibition
by 17-AAG, as evidenced results obtained elsewhere
[10,30]. 17-AAG inhibtis the protein HBP21 in ARPE-19
cells, which can interact with Hsp70 [31] and Hsp90
(unpublished results). Therefore, 17-AAG inhibited the
function of Hsp90, but did not do so by changing the
expression of Hsp90. Only a few Hsp90 client proteins,
and no signaling proteins, were identified, probably
because they were present in only small amounts [10].
Dongweon Song et al. [11] also found no alteration in the
expression of signaling proteins upon exposure to a new
Hsp90 inhibitor, IPI-504. Most of the proteins identified
herein have no clear relationship with Hsp90, so 17-AAG
may affect the Hsp90 client proteins that were not identi-
fied and thus indirectly affect the proteins that were iden-
tified herein.
Peroxiredoxin-1, Peroxiredoxin-2, Peroxiredoxin-3 and
Peroxiredoxin-4, which are antioxidants, were also down-
regulated, while superoxide dismutase (SOD) was upreg-
ulated. SOD assay also reveals that SOD activity was
upregulated in RPE cells upon exposure to 17-AAG for 16
h. These results suggest that 17-AAG may induce oxida-
tive stress by inhibiting antioxidants. The Hsp90 inhibi-
tors, geldanamycin and radicicol, both induce oxidative
stress in cells [32-34]. Other researchers have found that
each of the four Peroxiredoxins has a proliferative effect,
and may be involved in the development or progression
of cancer. Peroxiredoxin-4 also can activate NF-κB and c-
Jun N-terminal kinase, and induces proliferation in fibro-
blasts [35,36], suggesting that the inhibition of the four
proteins facilitates the antiproliferative effect of 17-AAG.
Proteins whose expression was identified as altered by
2-DE were analyzed further by IPA. Canonical pathway
analysis indicated that oxidative stress was the top func-
tion in the list. Gene Ontology (GO) analysis revealed
that the molecular function that contained the most iden-
tified proteins was oxidoreductase. Accordingly, Hsp70
and Hsp90α were greatly upregulated upon 16 h of treat-
ment with 3 μM 17-AAG probably by oxidative stress.
Finally, the proteomics results obtained using 17-AAG
and other Hsp90 inhibitors were compared across various
cell lines. The results for only a few proteins matched pre-
vious results [[6,10,25,37] and [38]], probably because of
differences in the cell lines, treatment times and concen-
trations. Although IPA analysis reveals little in common
among the proteins that were altered by other Hsp90
inhibitors, oxidative stress was placed highly in most
function lists [[6,10,25,37] and [38]].
HSP90 has been reported to be strongly associated with
oxidative stress. For example, Hsp90 protects against
CYP2E1-dependent oxidant stress in HepG2 cells [26].
HSP90 inhibitors can induce oxidative stress in RPE cells
and other cells, including radicicol and GA [34]. GA has a
benzoquinone moiety that forms ROS (reactive oxygen
species). Additionally, GA has been found to bind to GSH
(glutathione), form stable GSH adducts and deplete cellu-
lar GSH. GA has been shown to generate superoxide. The
applicatin of GSH has been reported to increase the resis-
tance of cancer cells to benzoquinone ansamycin com-
pounds [39]. Since 17-AAG is a derivative of the
ansamycin geldanamycin and has a similar structure to
that of GA, 17-AAG may also induce oxidative stress in
many cell lines, including RPE cells.
Figure 10 Change in SOD activity after 3 μM 17-AAG treatment 
for 16 h, 24 h and 48 h. The ARPE-19 cells were treated with 3 μM 17-
AAG for 16, 24 or 48 h, and then SOD activity was determined by an 
SOD Assay Kit-WST. The SOD activity in RPE cells is upregulated in 16 h 
and downregulated in 24 h, as determine by comparison with control. 
However, the SOD activity in RPE cells is almost fully recovered in 48 h. 
Values are expressed as mean ± SD. *, p < 0.05, indicates a significant 
difference from control. NS, no significant difference from control.Yao et al. Journal of Biomedical Science 2010, 17:30
http://www.jbiomedsci.com/content/17/1/30
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Conclusions
In conclusion, 17-AAG has a powerful antiproliferative
effect on ARPE-19 cells by inducing cell apoptosis and
cell cycle arrest. Although many other mechanisms per-
tain, low doses of 17-AAG may inhibit the proliferation of
ARPE-19 cells in part by inducing oxidative stress in the
early period of exposure. Although more experiments
must be carried out to determine the precise role of oxi-
dative stress in the mechanism of action of 17-AAG, 17-
AAG was shown to reduce the proliferation of ARPE-19
cells and may be an excellent candidate for treating eye
diseases associated with proliferative RPE cells, including
PVR.
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